The SHEAF study (Self measurement of blood pressure at Home in the Elderly: Assessment and Follow-up) is a 3-year prospective cohort study of French elderly (у60 years) hypertensive patients designed to assess whether home blood pressure (HBP) measurement provides additional prognostic information over office blood pressure (OBP) in terms of cardiovascular mortality and morbidity. The objective of the present work is to describe the baseline data of the population enrolled in the SHEAF study with special emphasis on blood pressure control in treated hypertensives. Methods: During the 2-week initial inclusion phase, baseline demographics, cardiovascular risk factors, antihypertensive treatments as well as office and home blood pressure were recorded. Baseline OBP was assessed using a mercury sphygmomanometer (three consecutive measurements during two visits performed 2 weeks apart). HBP was performed over a 4-day period (three consecutive measurements in the morning and in the evening). Results: A total of 4939 (95%) of the 5211 patients included in the SHEAF study were treated with at least one antihypertensive drug. Their ages ranged from 60 to 99 years (mean age 70 ؎ 7 years); 49% were men, 12% had a previous history of coronary artery disease, 14% diabetes and 43% a treated dyslipidaemia. A total of 45% of the treated patients received a single antihypertensive drug, 34% two drugs, 21% three drugs or
Introduction
The prevalence of hypertension, one of the most prominent risk factors for cardiovascular disease, is high in industrialised countries. In the French IHPAF study (evaluation of incidence and prevalence of hypertension in a large cohort of active workers) conducted by the French society of hypertension, 50% of men aged over 50 years of age were hypertensives. 1 Epidemiological studies conducted in the USA as well as in Europe show that about 65 to 70% of subjects with hypertension were aware of it. 2 Among them 60% were receiving treatment and less than 30% had their hypertension controlled and reached the recommended target blood pressure of Journal of Human Hypertension 140 mm Hg for systolic blood pressure (SBP) and 90 mm Hg for diastolic blood pressure (DBP). 2 These data are worrying as positive effects of blood pressure lowering on mortality and morbidity from cardiovascular disease have been demonstrated in randomised controlled trials for young patients with essential mild to moderate hypertension, 3 but also for elderly and very elderly patients with systolodiastolic hypertension 4, 5 and isolated systolic hypertension. 6, 7 Such findings are not due to a lack of choice in antihypertensive treatments as several drug classes available worldwide are recommended for the initiation and maintenance of antihypertensive therapy. 2, 8 They may be due to the lack of awareness by physicians of the blood pressure targets to reach. Moreover concerns have been raised that lowering DBP too much may increase the risk for coronary events-the so-called J-curve hypothesis. 9 But all available evidence supports the value of the reduction of systolic and diastolic blood pressure at all ages to the levels achieved in randomised controlled trials (140/90 mm Hg), even in isolated systolic hypertension. [4] [5] [6] [7] Moreover, for hypertensive diabetics, arterial blood pressure should be reduced below 130/85 mm Hg. 2 Poor compliance with longterm treatment known to be common among hypertensive patients may also explain poor blood pressure control. 10 However there is the possibility that office blood pressure (OBP) measurements caused a stress reaction and a pressor response known as the white coat effect, which lead to distorted view of blood pressure control. 11, 12 The SHEAF study (Self measurement of blood pressure at Home in the Elderly: Assessment and Follow-up) is a prospective cohort study of French elderly hypertensive patients designed to assess whether home blood pressure (HBP) measurement provides additional prognostic information over OBP in terms of cardiovascular mortality and morbidity. 13 The objective of the present work is to describe the baseline data of the population of treated hypertensives enrolled in the SHEAF study with special emphasis on blood pressure control at the doctor's office as well as at home.
Patients and methods

Design and patients
The SHEAF study is a 3-year prospective cohort study conducted in France. Subjects of both sexes were recruited by general practitioners and included when they fulfilled the following inclusion criteria:
• age у60 years;
• primary permanent hypertension defined by the current use of prescribed antihypertensive treatment or, in the absence of treatment, by either office SBP у140 mm Hg or office DBP у90 mm Hg twice apart during the year preceding inclusion;
• arm size allowing the use of a standard cuff;
• ability to perform an appropriate number of blood pressure measurements at home with the device of the study (see below); • absence of any threatening disease, or absence of recent (last 3 months) acute cardiovascular events in the last 6 months (myocardial infarction, stroke).
The study comprised two successive phases:
• The first phase consisted of a 2-week period of evaluation with two separated visits performed 2 weeks apart. Demographic data, medical history of the patients, cardiovascular risk factors and antihypertensive treatments were recorded as well as OBP and HBP levels (see below). This phase took place from February 1998 to March 1999.
• The second phase is a 3-year follow-up of patients.
Follow-up visits are performed every year by the patients' general practitioners. There is no specific recommendation with regards to management of hypertension and blood pressure goal. The primary end-point is cardiovascular mortality. Secondary end-points are total mortality and the combination of cardiovascular mortality, myocardial infarction, stroke, transient ischaemic attack, hospitalisation for angina or heart failure, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG). This phase will end in late 2001.
Baseline data collection
For each patient, age, gender, height and weight were recorded. Obesity was defined as a body mass index Ͼ30 kg/m 2 . A history of coronary artery disease was defined as a self-reported history of doctordiagnosed myocardial infarction, angina, PTCA or CABG. A history of cardiac failure, peripheral vascular disease (PVD) or stroke was also recorded. Other cardiovascular risk factors were collected: current or former smoking habits, treated hypercholesterolaemia and diabetes. Names of current classes of prescribed antihypertensive drugs were recorded
Blood pressure measurements and control of hypertension
Office blood pressure measurement: During the first phase, the physician, using a mercury sphygmomanometer with the patient in the sitting position after a 5-min rest, took triplicate blood pressure measurements at each visit. SBP was taken at phase 1 of Korotkoff sounds and DBP at phase 5 of Korotkoff sounds. The mean of the six readings was considered as office baseline blood pressure for each patient. Hypertension was considered as controlled at office when a patient treated with at least one antihypertensive drug exhibited a SBP Ͻ140 mm Hg and a DBP Ͻ90 mm Hg.
Home blood pressure measurement: HBP measurement was performed during the first phase of the study. HBP measurement was planned over a 4-day period chosen at the patient's convenience. Every day a series of three consecutive measurements was requested in the morning (8.00 am) and repeated in the evening (8.00 pm). Measurements were performed in the sitting position after a 5-min rest. The OMRON HEM 705 CP device which is a printer equipped, semi-automatic, digitised device based on the oscillometric method was used by all the subjects. This device had been previously validated by comparison to a mercury sphygmomanometer. 14 Patients were included in the study only if they exhibited at least 15 valid measurements, with at least six measurements in the morning and six measurements in the evening. For each included patient, the mean of all the available home measurements was taken as the HBP value. Hypertension was considered as controlled at home when a patient treated with at least one antihypertensive drug exhibited a SBP Ͻ135 mm Hg and a DBP Ͻ85 mm Hg.
Statistical analysis
Quantitative data are summarised as means Ϯ one standard deviation and qualitative data as percentages. The between-group comparisons were carried out using analysis of variance for quantitative data and chi-square test for qualitative data. In order to control an overall 0.05 alpha risk when interpreting results of Tables 2 to 5, the Simes procedure 15 was used and led to consider significant all nominal Pvalues Ͻ0.0365.
Results
Patients
A total of 5649 subjects were recruited between February 1998 and March 1999 by 1428 general practitioners. Among them, 186 subjects were excluded in the below 60 age group and 252 subjects for nonvalid HBP. Thus 5211 subjects (2565 men and 2646 women), mean age 70 Ϯ 7 years, with valid HBP were included. Their general characteristics are shown in Table 1 . Hypertension duration was 11 Ϯ 8 years. Among these patients 12% had a previous history of coronary artery disease, 14% had diabetes, 33% a history of tobacco consumption and 43% a treated dyslipidaemia. Among subjects with treated dyslipidaemia, 19% were only on diet, 42% were treated by fibrates and 39% by statins. A total of 4939 subjects (95%) received at least one antihypertensive drug. At the first visit, mean OBP levels were 153 Ϯ 19/86 Ϯ 10 mm Hg. At the second visit, mean OBP levels were 150 Ϯ 17/84 Ϯ 10 mm Hg (mean of the two visits: 152 Ϯ 17/85 Ϯ 9 mm Hg). A digit preference for 0 (56% of measurements for SBP and 57% for DBP) and for 5 (25% of measurements The characteristics of the treated hypertensives were different from those of the 272 untreated hypertensives (5%): despite similar or even higher blood pressure levels, untreated hypertensives exhibited a more favourable risk profile (Table 1 ). The characteristics of the treated hypertensives according to age are described in Table 2 . Very elderly subjects were more often women and presented with a history of cardiovascular and coronary artery disease. Systolic blood pressure was higher in older subjects whatever the method of measurement used. Of the 726 (15%) of subjects, 74% were diabetics treated with oral antidiabetic drug, 17% insulin or 19% with diet alone. The between-group comparison of the patients according to the presence or absence of diabetes is shown in Table 3 . These diabetic subjects were mainly men (56% vs 48%, P = 0.001). They exhibited more often other cardiovascular risk factors than subjects without diabetes such as obesity, hypercholesterolaemia and smoking. Moreover they often had a history of previous cardiovascular or coronary artery disease.
Current antihypertensive treatment
Among the 4939 subjects receiving at least one antihypertensive drug, 2224 (45%) were taking a single drug, 1696 (34%) two drugs, 741 (15%) three drugs and 278 (6%) were taking four or more drugs. Overall the most common single line treatment was ACE inhibitors (29%) then beta-blockers (21%), calcium antagonists (18%) and diuretics (14%). Among those receiving two drugs, the most common combination was an ACE inhibitor with a diuretic (24%) and the second most common a beta-blocker with a diuretic (18%). Among the patients receiving three antihypertensive drugs, 79% received a diuretic for the treatment of their hypertension. The number of prescribed antihypertensives was higher in older subjects (Table 2) . Diabetic hypertensives more often needed three or more antihypertensive drugs (29% vs 19%, P = 0.001, Table 3 ).
As shown in Table 4 subjects receiving three drugs or more were older than subjects receiving one single drug. Hypertension duration was longer even when adjusted for age. These patients exhibited higher blood pressure levels. They were more likely obese or diabetics and more often treated for hyperlipidaemia; a history of coronary artery disease, stroke, congestive heart failure or PVD was more frequently found. All these differences were statistically significant even when adjusted for age.
Control of hypertension
Overall, 1150 of the 4939 treated hypertensives (23%) were normalised at office (SBP Ͻ140 mm Hg and DBP Ͻ90 mm Hg) and 1343 subjects (27%) had a HBP less than 135/85 mm Hg. The proportion of subjects with controlled OBP decreased from 26% in subjects aged between 60 and 69 years, to 21% in both subjects aged between 70 and 79 years and elderly subjects aged 80 and over. At home this proportion decreased respectively from 30% to 24%
and to 21% (Table 2) . Whatever the threshold used to define blood pressure control (140/90 mm Hg and 130/85 mm Hg at the doctor's office and 135/85 mm Hg at home), blood pressure was less often adequately controlled in diabetic patients ( Table 3) . The comparison between controlled and uncontrolled patients at the doctor's office is shown in Table 5 . The two groups were significantly different for age, presence of diabetes and history of PVD. Subjects whose blood pressure was not adequately controlled were older (70 years vs 69 years, P Ͻ 0.001), more often had diabetes (15% vs 12%, P = 0.004) and a history of PVD (6% vs 5%, P Ͻ 0.015). Moreover they received multiple antihypertensive therapy more often than subjects with blood pressure normalised (23% with three drugs or more vs 14%, P Ͻ 0.001).
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Discussion
Population
The SHEAF study included 5211 patients with valid HBP measurements. This represents the largest cohort having used the HBP measurement technique in hypertensives. A high level of cardiovascular risk factors characterises the SHEAF population as one half of the patients exhibited at least one cardiovascular risk factor in addition to age and hyperten- sion. The features of the population of this large cohort are not very different from those of elderly hypertensive patients enrolled in large controlled trials such as the SHEP trial or the SYST-EUR trial. 6, 7 In a French large open-labelled study 16 enrolling 13147 hypertensives aged 68 years, 15% of the patients had a history of diabetes, 10% a coronary artery disease, 4% a history of congestive heart failure and 46% were overweight, these characteristics being close to those of the SHEAF population. According to published guidelines 2,8 these high risk patients have to receive not only antihypertensive treatment but also adequate care for diabetes, high cholesterol and associated cardiovascular diseases. As some of the patients are already receiving several antihypertensive drugs, this raises the problem of the addition of other medications and of drug compliance. It may seem obvious that compliance should be better in patients treated with a single drug rather than several, however results of one study suggested the opposite: compliance increased with the number of drug prescribed. 17 Blood pressure rises with age. 18 This increase is more important for SBP than for DBP until age 50 then DBP remains stable or even decreases while SBP continues to increase. Isolated systolic hypertension is increasingly prevalent with age especially in those aged 60 years and above. There is compelling evidence that SBP is a determinant of cardiovascular disease at least as important as DBP and benefits of treatment have been demonstrated among older patients with classical hypertension as well as among older patients with isolated systolic hypertension. [4] [5] [6] [7] In the SHEAF study there was an increase with age of SBP while DBP decreased and pulse pressure increased. This may be linked to the higher prevalence of systolic hypertension in the elderly. Alternatively as our patients were already treated an underestimation of the prognostic value of SBP may have led physicians to neglect SBP levels while focusing on DBP control.
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Current antihypertensive treatment
A total of 45% of subjects were treated with antihypertensive monotherapy while 21% of subjects received three or more drugs. This last figure is relatively high when compared to the results of the Health Survey conducted in England in 1994. 19 In this survey, among subjects aged over 65 who received a treatment for hypertension, only 6% were taking three or more drugs. This discrepancy may be explained by the improvement of the management of hypertension between 1994 and 1998 with upward trends in treatment of blood pressure. In the SHEAF trial there was a predominant use of ACEinhibitors (29%) and beta-blockers (21%) for those receiving monotherapy, which is rather different from the figures published in the Health Survey for England in which diuretics (42%) were the most common single-line treatment. This may be reliable in the publication of the main prospective studies using ACE-inhibitors first in patients with heart failure 20 or myocardial infarction 21 and more recently in hypertensive patients. 22 Finally the frequent use of a diuretic for those receiving two drugs is in keeping with the recommendations made in the majority of recently published guidelines for the management of hypertension.
2,8
Blood pressure control
The goal of treatment has been recommended to be below 140/90 mm Hg by the published guidelines and in older patients this goal should be the same as in younger patients. 2, 8 Our study shows that only 23% of treated subjects have a satisfactory clinic blood pressure control. This finding is consistent with poor blood pressure control observed in treated hypertensive patients both in the USA and in Europe. From the 1991-1994 NHANES III the percentage of Americans with high blood pressure controlled to below 140/90 mm Hg was 27%. 2, 23 In the Pamela study clinic blood pressure control was satisfactory in 28% of treated hypertensive patients with blood pressure not exceeding 140/90 mm Hg. 24 In the French PHARE 2 study, only 28% of the 1566 treated hypertensives aged over 65 had a blood pressure lower than 140/90 mm Hg. 25 The proportion of treated hypertensives whose blood pressure was found to be well controlled at home was only slightly greater than those whose blood pressure was found to be satisfactory in the office. Thus as already shown in the Pamela study, 24 the poor blood pressure control at office is not due to white coat effect but indicates a real lack of blood pressure control despite the antihypertensive drugs prescription.
The identification of predictive factors of blood pressure control was not conclusive. Neither gender nor hypertension duration was linked to blood pressure control. Patients with poor blood pressure control were statistically significantly older but the within-group 1-year difference does not appear to be clinically relevant. In contrast, the presence of diabetes was related to poor blood pressure control. As the coexistence of diabetes and hypertension is known to lead to an increased risk of cardiac death and cardiac morbidity, the majority of recently published guidelines for hypertension have recommended in reference to the UKPDS study 26 to reduce arterial blood pressure more aggressively in diabetic patients. 2, 8 In spite of these recommendations, using the 140/90 mm Hg threshold, the percentage of diabetics with OBP lower than 140/90 mm Hg was significantly less than that of nondiabetics. Moreover the 130/85 mm Hg goal that is recommended for diabetics, was reached by only 6% of our diabetics. 2 Recent large prospective treatment trials have clearly shown that a combination of several antihypertensive agents is needed to control blood pressure. In the HOT study, about 60% of the patients received at least two antihypertensive drugs to reach the predefined target blood pressure. This figure increased with the severity of the target DBP value. 27, 28 In the SHEAF study, patients treated with several antihypertensives were significantly less controlled than patients in monotherapy, a result in apparent opposition with the HOT data. 28 As the SHEAF study is not an intervention trial but an observational study in which baseline blood pressure levels prior to antihypertensive treatment are unknown, patients receiving several drugs may have had a more severe hypertension.
Of the patients with poor blood pressure control 40% were on single-line treatment. This may be due to a superficial knowledge by the physicians of the goal to reach with antihypertensive treatments or to
Journal of Human Hypertension a reluctance among physicians to prescribe more intensive drug therapy even in those with poor blood pressure control. Finally inadequate blood pressure control addresses the problem of poor patient compliance. It has already been shown that in asymptomatic diseases such as hypertension the rate of treatment compliance is frequently low 10 and that loss of efficacy represents the principal risk of non-compliance. 29 
Conclusion
The hypertensive patients enrolled in the SHEAF study were elderly patients aged 70 years. In this population the number of patients whose blood pressure was normalised is in agreement with published data on younger patients: less than 30% were normalised whatever the method of blood pressure measurement used, office or home. Presence of associated cardiovascular risk factors and especially diabetes did not change these data. As the beneficial effect of antihypertensive treatment is obvious, the data of this study must lead to a closer and more rigorous management of elderly hypertensives.
